Overview

Double-Dose Firmonertinib in EGFR-Mutant Advanced NSCLC Achieving Stable Disease After Standard-Dose First-Line Firmonertinib

Status:
NOT_YET_RECRUITING
Trial end date:
2032-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of Firmonertinib 160 mg once daily in patients with EGFR-mutant, advanced NSCLC who achieve stable disease after first-line Firmonertinib 80 mg for 8 weeks.
Phase:
PHASE2
Details
Lead Sponsor:
Peking University Cancer Hospital & Institute